Radioiodine Ablation for Differentiated Thyroid Cancer—None, One Dose or Two?

British Thyroid Association, Royal College of Physicians, 2007 British Thyroid Association, Royal College of Physicians, 2002 Gerrard, 2008, Thyroid cancer guidelines – what's new?, Clin Oncol, 20, 264, 10.1016/j.clon.2008.01.005 Cobin, 2001, AACE/AAES medical/surgical guidelines for clinical practice: management of thyroid carcinoma, Endocr Pract, 7, 202, 10.4158/EP.7.3.202 Cooper, 2006, Management guidelines for patients with thyroid nodules and differentiated thyroid cancer, Thyroid, 16, 1, 10.1089/thy.2006.16.109 Pacini, 2005, Post-surgical use of radioiodine (131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report, Eur J Endocrinol, 153, 651, 10.1530/eje.1.02014 Pacini, 2006, European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium, Eur J Endocrinol, 154, 787, 10.1530/eje.1.02158 Luster, 2008, Guidelines for radioiodine therapy of differentiated thyroid cancer, Eur J Nucl Med Mol Imaging, 35, 1941, 10.1007/s00259-008-0883-1 Mazzaferri, 1994, Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer, Am J Med, 97, 418, 10.1016/0002-9343(94)90321-2 Samaan, 1992, The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patients, J Clin Endocrinol Metab, 75, 714, 10.1210/jc.75.3.714 Sawka, 2004, Clinical review 170: a systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer, J Clin Endocrinol Metab, 89, 3668, 10.1210/jc.2003-031167 Creutzig, 1987, High or low dose radioiodine ablation of thyroid remnants?, Eur J Nucl Med, 12, 500, 10.1007/BF00620474 Johansen, 1991, Comparison of 1073MBq and 3700MBq iodine-131 in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid cancer, J Nucl Med, 32, 252 Bal, 2004, Radioiodine dose for remnant ablation in differentiated thyroid carcinoma: a randomized clinical trial in 509 patients, J Clin Endocrinol Metab, 89, 1666, 10.1210/jc.2003-031152 Maenpaa, 2008, Low vs. high radioiodine activity to ablate the thyroid after thyroidectomy for cancer: a randomized study, PLoS ONE, 3, e1885, 10.1371/journal.pone.0001885 Kukulska, 2006, Optimization of 131I ablation in patients with differentiated thyroid carcinoma: comparison of early outcomes of treatment with 100mCi versus 60mCi, Endokrynol Pol, 57, 374 Schlumberger, 1986, Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma, J Clin Endocrinol Metab, 63, 960, 10.1210/jcem-63-4-960 Maxon, 1983, Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer, N Engl J Med, 309, 937, 10.1056/NEJM198310203091601 Maxon, 1999, Detection of residual and recurrent thyroid cancer by radionuclide imaging, Thyroid, 9, 443, 10.1089/thy.1999.9.443 Beierwaltes, 1984, An analysis of ‘ablation of thyroid remnants’ with I-131 in 511 patients from 1947–1984: experience at University of Michigan, J Nucl Med, 25, 1287 Robbins, 2005, The evolving role of 131I for the treatment of differentiated thyroid carcinoma, J Nucl Med, 46, 28S Doi, 2007, Ablation of the thyroid remnant and I-131 dose in differentiated thyroid cancer: a meta-analysis revisited, Clin Med Res, 5, 87, 10.3121/cmr.2007.763 Mazzaferri, 2004, A randomized trial of remnant ablation – in search of an impossible dream?, J Clin Endocrinol Metab, 89, 3662, 10.1210/jc.2004-0739 Schlumberger, 2004, Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective, Eur J Endocrinol, 150, 105, 10.1530/eje.0.1500105 Sampson, 2007, Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis, Cancer, 110, 1451, 10.1002/cncr.22956 Cady, 1988, An expanded view of risk-group definition in differentiated thyroid carcinoma, Surgery, 104, 947 Hay, 1993, Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989, Surgery, 114, 1050 Mazzaferri, 2007, Management of low-risk differentiated thyroid cancer, Endocr Pract, 13, 498, 10.4158/EP.13.5.498 Verburg, 2009, Why radioiodine remnant ablation is right for most patients with differentiated thyroid carcinoma, Eur J Nucl Med Mol Imaging, 36, 343, 10.1007/s00259-008-0997-5 Tuttle, 2009, Can risk-adapted treatment recommendations replace the one size fits all approach for early-stage thyroid cancer patients?, Oncology, 23, 1 Rubino, 2003, Second primary malignancies in thyroid cancer patients, Br J Cancer, 89, 1638, 10.1038/sj.bjc.6601319 Sandeep, 2006, Second primary cancers in thyroid cancer patients: a multinational record linkage study, J Clin Endocrinol Metab, 91, 1819, 10.1210/jc.2005-2009 Brown, 2008, The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer, J Clin Endocrinol Metab, 93, 504, 10.1210/jc.2007-1154 Hay, 2002, Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940–1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients, World J Surg, 26, 879, 10.1007/s00268-002-6612-1 McHenry, 1990, Selective postoperative radioactive iodine treatment of thyroid carcinoma, Br J Surg, 77, 110, 10.1002/bjs.1800770140 Hay, 2008, Perspective: the case against radioiodine remnant ablation in patients with well-differentiated thyroid carcinoma, J Nucl Med, 49, 1395, 10.2967/jnumed.108.052654 Morris, 1998, Localized well-differentiated thyroid carcinoma: survival analysis of prognostic factors and (131) I therapy, Ann Surg Oncol, 5, 329, 10.1007/BF02303496 Sawka, 2008, An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer, Endocrinol Metab Clin North Am, 37, 457, 10.1016/j.ecl.2008.02.007 Taylor, 1998, Outcome after treatment of high-risk papillary and non-Hurthle-cell follicular thyroid carcinoma, Ann Intern Med, 129, 622, 10.7326/0003-4819-129-8-199810150-00007 Kloos, 2005, A single recombinant human thyrotropin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later, J Clin Endocrinol Metab, 90, 5047, 10.1210/jc.2005-0492 Hyer, 2007, Salivary gland toxicity after radioiodine therapy for thyroid cancer, Clin Oncol, 19, 83, 10.1016/j.clon.2006.11.005 Wong, 1990, Ablative radioactive iodine therapy for apparently localized thyroid carcinoma. A decision analytic perspective, Endocrinol Metab Clin North Am, 19, 741, 10.1016/S0889-8529(18)30319-0 Dragoiescu, 2003, Feasibility of a randomized trial on adjuvant radio-iodine therapy in differentiated thyroid cancer, Clin Endocrinol (Oxf), 58, 451, 10.1046/j.1365-2265.2003.01738.x